92 stories found
Gilead Sciences recently received its third regulatory approval in under four months, prompting analysts to question whether the market is undervaluing the company's operational turnaround.
The U.S. Food and Drug Administration has granted approval for Gilead Sciences' new once-daily oral medication for treating HIV.
Pharmaceutical giant Gilead Sciences is experiencing a significant financial recovery after overcoming a prolonged period of declining performance. Analysts attribute the turnaround primarily to a key product or strategic initiative that is driving substantial revenue growth.
Several executives from various companies, including CoreWeave, Braze, Trinet, Heritage Insurance, Goosehead Insurance, Crowdstrike, Palladyne AI, and Acm Research, have sold significant amounts of their company stock.
Gilead Sciences has quietly become recognized as one of the most underrated turnaround stories in the healthcare sector, generating excitement on Wall Street.
A potential partnership between Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD) is being explored as a possible new engine for growth in the pharmaceutical industry.
Gilead Sciences has announced a dividend of $0.82 per share.
Gilead Sciences reported an 8% increase in second-quarter sales, successfully beating Wall Street's financial estimates.
A head-to-head clinical trial has demonstrated that ViiV Healthcare's Dovato is as effective as Gilead Sciences' Biktarvy, indicating comparable efficacy between the two treatments.
An article explores whether the current bearish sentiment surrounding pharmaceutical giants Pfizer and Gilead Sciences presents a potential contrarian investment opportunity.
Cantor Fitzgerald has reiterated its Overweight rating on Gilead Sciences (GILD) following positive results from its HIV trial.
An article provides an analysis on whether Gilead Sciences, Inc. (GILD) stock is currently a good investment for potential buyers.
Gilead Sciences has released new findings from a post hoc analysis, providing additional data related to their research.
Gilead Sciences (GILD) is scheduled to showcase new data related to its cancer therapy research, indicating potential advancements in oncology.
Maxim has upgraded Gilead Sciences (GILD) to a ‘Buy’ rating. This reflects a positive outlook on the pharmaceutical company's stock.
Morgan Stanley has reevaluated its outlook for Gilead Sciences following the company's recent quarterly report, providing an updated perspective on its financial performance and future prospects.
Gilead Sciences, Inc. (GILD) has seen its outlook cut sharply due to significant $11.5 billion IPR&D (In-Process Research and Development) and financing costs, impacting its financial projections.
Gilead Sciences has revised its 2026 sales forecast upwards but simultaneously lowered its profit outlook, citing recent acquisitions as the primary reason for the adjustments.
Analysts are divided on the future performance of Gilead Sciences stock, with varying bullish and bearish sentiments from Wall Street.
Jim Cramer offered his latest investment advice, highlighting specific stock recommendations like Wells Fargo, Nokia, and Broadcom, and shared his outlook on the market's "remarkable" rally and the upcoming big earnings week. He also discussed strategic moves for his Investing Club.
Gilead Sciences has once again extended its tender offer to acquire Arcellx.
Gilead Sciences (GILD) announced its intention to acquire Tubulis for $5 billion, a strategic move to strengthen its oncology drug pipeline.
An analysis explores whether Gilead Sciences (GILD) qualifies as a top low-volatility blue-chip stock for current investment portfolios.
Galapagos NV announced it has signed an agreement with Gilead Sciences concerning assets related to Ouro Medicines. The details of the agreement were not immediately specified.
Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.
Gilead Sciences has announced its acquisition of Ouro Medicines and a subsequent collaboration with Galapagos on the newly purchased assets, as reported by the Wall Street Journal.
A report highlights notable healthcare headlines for the week, focusing on developments related to pharmaceutical companies Viatris, Novo Nordisk, and Gilead Sciences.
Gilead Sciences has announced a $7.8 billion payment to take full control of a promising multiple myeloma therapy, expanding its oncology portfolio.
Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.
Barclays has adopted a neutral stance on Gilead Sciences, acknowledging its strategic refocus but maintaining a cautious outlook.
Financial analysts question whether Gilead's expanding operational costs can be sustained by its pharmaceutical sales pipeline.
Gilead Sciences board member Welters sold roughly $2.68 million in company shares.
Gilead Sciences is experiencing a surge in its HIV business, prompting questions about whether the company is becoming overly dependent on a single franchise for its overall success.
Multinational pharmaceutical company Gilead Sciences will cease the circulation of an innovative breast cancer drug in Greece starting January 1, 2027, citing a clawback mechanism that exceeds 100%.
The article examines if MacroGenics (MGNX) can transform Gilead Sciences (GILD)'s $10 million milestone payment into a significant catalyst for its pipeline development.
Seeking Alpha analysts have issued a series of upgrades and downgrades for several prominent technology companies, including Intel (INTC), AMD, Arista Networks (ANET), and Gilead Sciences (GILD).
Gilead Sciences reported a 10% jump in Q2 base sales, driven by strong growth in its HIV and oncology segments, despite a decline in Veklury sales.
Gilead Sciences is evaluating Yeztugo as a potential significant growth driver for its HIV treatment portfolio, indicating a focus on expanding its market presence in the sector.
Pharmaceutical companies Johnson & Johnson and Gilead Sciences were among those receiving drug recommendations from the European Union this week. These recommendations are part of the EU's regulatory process for new and existing medicines.
Many investors are still treating Gilead Sciences as a legacy HIV stock, but the company's four new drug launches this year could significantly change its market perception and valuation.
A potential FDA milestone could unlock a significant new growth driver for Gilead Sciences (GILD).
Gilead Sciences (GILD) and Lakefront Biotherapeutics have jointly acquired Ouro Medicines to further advance their pipeline of autoimmune treatments.
Gilead Sciences' drug Livdelzi has garnered attention for demonstrating long-term efficacy and safety in its trials.
Gilead Sciences has secured FDA approval for Hepcludex, marking it as the first approved treatment for hepatitis delta virus (HDV), offering a new therapeutic option for patients.
Gilead Sciences' drug Hepcludex has received FDA approval for the treatment of chronic Hepatitis Delta Virus (HDV) infection, marking a significant development in health.
Gilead Sciences anticipates reporting a loss this year, primarily driven by significant expenses related to acquired research and development.
Gilead Sciences is targeting $1 billion in sales for its drug Yeztugo by 2026 and has raised its overall base business outlook to between $29.4 billion and $29.8 billion.
Several companies, including ATN International, EVERTEC, Montrose Environmental, Phibro Animal, UGI, and TKO, have released their latest quarterly financial results. While some companies reported earnings that beat analyst expectations, others missed revenue or EPS forecasts.
Gilead Sciences is reportedly set to acquire Arcellx, a move that would expand Gilead's portfolio and strategic capabilities within the biopharmaceutical sector.
Citi has increased its price target for Gilead Sciences (GILD) in anticipation of the company's upcoming Q1 Biopharma preview.
Morgan Stanley has revised its outlook for Gilead Sciences, citing updated biopharma models that suggest a more positive financial trajectory for the company.
Seeking Alpha analysts have released their latest stock recommendations, including upgrades and downgrades for companies such as Palantir (PLTR), Rivian (RIVN), Gilead Sciences (GILD), and Intel (INTC). Additionally, unusual put options volume for Intel (INTC) has been observed, interpreted by some as a bullish signal for the company.
Gilead Sciences has provided details on its deals with Tubulis, Ouro, and Arcellx, which are seen as pipeline catalysts, with further updates expected by 2026.
Investors are anticipating several key earnings reports from major companies, including PG&E Corporation, Procter & Gamble, CenterPoint Energy, and Gilead Sciences, that are set to be released after the market closes on Thursday.
Gilead Sciences is set to acquire biotech firm Ouro Medicines in a deal valued at $2.2 billion, marking its first TCE asset acquisition and aiming to boost its T cell therapy capabilities for autoimmune diseases.
Gilead Sciences has announced plans to acquire Ouro Medicines and will subsequently collaborate with Galapagos on the assets obtained through the purchase.
Gilead Sciences, Inc. (GILD) is seeing its growth prospects bolstered by recent analyst upgrades, indicating positive sentiment in the market.
Gilead Sciences' experimental HIV treatment has demonstrated low discontinuation rates in recent studies, indicating potential for improved patient adherence.
Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.
Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.
Analysts are sharing their opinions and insights on Gilead Sciences (GILD) following its recent earnings report.
Analysis examines whether Gilead Sciences shares are currently outpacing broader market gains, evaluating recent earnings, pipeline developments, and sector trends.
The U.S. Food and Drug Administration has approved Gilead Sciences’ new once-daily combination medication for treating HIV infection. The approval aims to simplify long-term antiretroviral therapy and improve patient adherence.
Gilead Sciences is experiencing accelerating revenue growth, but questions are being raised regarding the cost-effectiveness and value of its recent acquisitions. The company's financial strategy is under evaluation.
Gilead Sciences has seen its stock price increase for the seventh straight trading session.
A U.S. appeals court has sided with Gilead Sciences, ruling against companies known as alternative funding programs that import medicines from overseas. This decision impacts the ability of these programs to bring Gilead medications into the country.
Bank of America has expressed support for Gilead Sciences, citing a key HIV statistic that is reportedly over 70%.
Gilead Sciences presented its second-quarter earnings call highlights, discussing its financial performance and updates on its pharmaceutical pipeline.
A new drug called lenacapavir, developed by Gilead Sciences, has shown nearly 100% effectiveness in preventing HIV infection with a twice-a-year injection, now facing the challenge of patient access.
Wall Street closed higher with all three major indices seeing gains. Analysts issued new research calls on various companies, including Nvidia, SpaceX, Tesla, Meta, and Microsoft.
Yahoo reports on Monday's top Wall Street analyst research calls, covering various companies including Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, and T-Mobile.
Gilead Sciences (GILD) has made a donation of Remdesivir to Uganda, contributing to public health efforts in the country.
Gilead Sciences and Lakefront have successfully finalized the acquisition of Ouro Medicines, a move expected to impact their respective portfolios and market positions.
An analysis examines the stock performance of Gilead Sciences in comparison to other companies within the healthcare sector. The report evaluates how Gilead's shares are faring relative to its industry counterparts.
Gilead Sciences has acquired Tubulis for $3.15 billion, a strategic move aimed at expanding its oncology portfolio. This acquisition underscores Gilead's commitment to strengthening its presence in cancer treatment and research.
The United States expresses cautious optimism for an agreement with Iran as Pakistan continues its mediation efforts to de-escalate tensions. However, a planned mediation trip to Iran has reportedly been put on hold, introducing uncertainty into the peace process.
Gilead Sciences has announced the pricing of its multi-tranche senior notes offering, totaling $3 billion.
Gilead Sciences' stock declined despite beating Q1 estimates, as the company now anticipates a loss per share for 2026.
Gilead Sciences held its annual meeting, where directors and executive pay received significant approval. The company also highlighted upcoming pipeline launches and potential acquisitions.
Gilead Sciences Inc. is reportedly increasing in popularity as a defensive stock choice among investors, indicating its perceived stability in the market.
Morgan Stanley has adjusted its outlook for Gilead Sciences, Inc. in anticipation of the company's first-quarter earnings report.
Gilead Sciences is projecting a $107 million headwind to its first-quarter earnings, attributed to recent research and development deals.
Analysts have released their latest stock recommendations, including upgrades and downgrades for companies such as Palantir, Rivian, Gilead Sciences, and Intel, alongside a specific buy prediction for QuantumScape (QS) stock before April 22, and analysis on Tesla's recent pullback.
Gilead Sciences announced its intention to acquire Tubulis, a company specializing in antibody-drug conjugates (ADCs), in a deal valued at $5 billion, expanding its oncology pipeline.
Galapagos NV and Gilead Sciences have entered into an agreement concerning the acquisition of Ouro Medicines, signaling a new development in the pharmaceutical sector.
US biopharmaceutical company Gilead Sciences has agreed to acquire Ouro Medicines for up to US$2.18 billion, gaining rights to an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences.
Gilead Sciences has finalized its acquisition of autoimmune biotech company Ouro Medicines for up to $2 billion and will collaborate with Galapagos on the purchased assets.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) The Globe and Mail
Gilead Sciences has announced the acquisition of Arcellx, a company specializing in CAR-T cell therapies, in a deal valued at $7.8 billion.
Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.
Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its presence in the biotechnology sector.